With the rapid development of new treatment modalities for multiple sclerosis (MS) there is a need to improve our ability to monitor disease progression over time. High resolution spectral-domain optical coherence tomography (OCT) has provided a means to both detect and monitor subtle changes in the retina and optic nerve in vivo. It is recognized that significant retinal ganglion cell (RGC) and retinal nerve fiber layer (RNFL) loss occurs in MS patients following an episode of optic neuritis (ON). A reduction in RNFL may be contrast, Garcia-Martin et al. reported that the RGC provided a means to both detect and monitor subtle changes in the retina and optic nerve in vivo. It is recognized that significant retinal ganglion cell (RGC) and retinal nerve fiber layer (RNFL) loss occurs in MS patients following an episode of optic neuritis (ON). A reduction in RNFL may be identified earlier due to transient edema in the acute stage of ON masking any early RNFL loss. However, the eventual magnitude of RNFL decline has been reported by some groups as more extensive than thinning of RGC layer (25% vs. 12%). In contrast, García-Martin et al. reported that the RGC provided a better predictor of axonal damage based on the expanded disability status scale (EDSS) disability scores. Several recent studies have also suggested that RGC layer thinning is a better measure of disease-related visual and general disability and brain atrophy and provides better sensitivity in monitoring longitudinal changes. Some of these studies, however, are limited in the application of their findings as they have either used different time intervals, used lower resolution time-domain OCT scanners, analyzed both eyes or included ON eyes, did not have longitudinal controls or chose to analyses only global RNFL (gRNFL) thickness. Significant thinning of RGC neuronal and axonal layers in non-ON (NON) eyes of MS patients is also now firmly established in cross-sectional studies. However, the results of longitudinal evaluation remains inconclusive. Therefore, the aim of the current investigation was firstly to verify if progressive neuronal and axonal loss of RGC does occur in NON eyes of relapsing remitting MS (RRMS) patients.
and secondly to determine which measure is the most sensitive to detect such changes. In addition to gRNFL thickness we also analyzed change in individual RNFL sectors and examined thinning of the retinal ganglion cell/inner plexiform layer (RGC/IPL) layer at different retinal eccentricities.

METHODS

Participants and Ethics

Consecutive relapsing-remitting MS (RRMS) patients with no history of clinical optic neuritis in at least one eye were enrolled. Patients with a history of other ocular or neurologic diseases that could affect the results, such as retinal and optic nerve disorders were excluded. All subjects were of Caucasian descent as previous studies have found that ethnicity effects mean RNFL thickness. 15,16 In addition, 20 age, sex, and race-matched healthy subjects were also recruited as controls, and were examined at baseline and 3-year follow-up. All patients underwent annual OCT scans and attended follow-up appointments for 3 years. For MS patients, while both eyes were scanned only NON eyes were analyzed, and in patients with no history of ON in either eye, one eye was selected at random. Only one eye was randomly selected and scanned in the control group.

This study was approved by the Human Research Ethics Committee of the University of Sydney (Sydney, Australia) and written informed consent was obtained from all participants. The study adhered to the tenets of the Declaration of Helsinki.

OCT Scans and Imaging Analysis

Optical coherence tomography scans were performed using Spectralis HRA+OCT (Heidelberg Engineering, Heidelberg, Germany) as described previously.3,17 The macula radial pattern protocol was used, which provided six slices in a star-like pattern; the central fovea being the midpoint of each slice (Fig. 1A). This created 12 radial sections around the central fovea, each 4.5 mm long and separated by 30° from each other. In total, 30° of visual angle (15° of eccentricity) were scanned. One hundred scans were averaged for each line scan to produce a resolution of 1536 pixels. For each OCT slice around the fovea, segmentation of the retinal layers was performed automatically using segmentation software. Retinal ganglion cell-IPL were analyzed together (Fig. 1B). All traces were inspected and manual corrections were made by one of the authors (EG), where necessary, for identifiable artifacts and clear segmentation errors. All manual corrections were checked by a second reviewer (AK). Both of the reviewers were blinded with respect to patients’ identity and scan order. The thickness of RGC/IPL was calculated at five eccentricities (between 2° and 10°) along each radial line (Fig. 1A). A mean value of all points and at each eccentricity was calculated.

A peripapillary circular scan was also performed to obtain the overall global (gRNFL) thickness measures as well as the RNFL thickness for nasal (nRNFL) and temporal (tRNFL) quadrants, the papillomacular bundle (PMB) and superior-temporal (TS), superior-nasal (NS), inferior-nasal (NI), and inferior-temporal (TI) sectors (Fig. 2). The follow-up function was activated to ensure the RGC/IPL and RNFL thicknesses were obtained at exactly the same locations as the baseline scans.

Statistics

Statistical analysis was performed using SPSS 22.0 (SPSS, Chicago, IL, USA). Comparisons were made between MS patients and controls using unpaired Student’s t-test as well as between baseline and follow-up measurements using repeated measures ANOVA. Sensitivity analysis was carried out using receiver operating characteristics (ROC) curves. Pearson correlation coefficient was used to measure statistical dependence between two numerical variables, while Pearson χ² coefficient was used for correlation of nominal variables such as sex. P less than 0.05 was considered statistically significant. The McNemar test was used to assess the difference between
Changes in the RGC Layer and RNFL of NON Eyes

TABLE 1. Demographics and Clinical Features of Study Participants

<table>
<thead>
<tr>
<th></th>
<th>MS Patients</th>
<th>Controls</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>45</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>15</td>
<td>7</td>
<td>0.818*</td>
</tr>
<tr>
<td>Female</td>
<td>30</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>39.9 ± 9.9</td>
<td>39.3 ± 12.0</td>
<td>0.655†</td>
</tr>
<tr>
<td>Disease duration, y</td>
<td>4.3 ± 2.8</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>EDSS</td>
<td>1.2 ± 1.3</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>History of ON</td>
<td>24</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

Values are mean ± SD. 42 MS patients were receiving disease-modifying treatments during the follow-up period, including interferon (n = 10), glatiramer acetate (n = 12), natalizumab (n = 5), fingolimod (n = 14) and dimethylfumarate (n = 1).

* McNeMar test.
† Nonpaired t-test.

the proportion of males and females in patients and controls groups. Variability of different parameters was assessed by the coefficient of variation (CV), calculated as SD divided by the mean of the measured values.

RESULTS

Forty-five consecutive RRMS patients with no history of clinical optic neuritis in at least one eye and 20 age, sex, and race-matched healthy subjects were enrolled. Demographics and clinical features of study participants are presented in Table 1. Of MS patients, 93% (42/45) were receiving a disease-modifying therapy for the duration of the study.

Baseline Analysis

Retinal ganglion cell/IPL and sectoral/gRNFL thicknesses for the groups of MS patients as well as healthy controls are presented in Table 2. The nine measurement parameters showed different degrees of intersubject variability with RGC/IPL thickness exhibiting the lowest CV in both groups.

In comparison with controls the RGC/IPL and tRNFL demonstrated highly significant thinning at baseline, while reduction of TI, TS, and PMB thickness just reached significance. All nasal segments were not significantly different from normal controls, which no doubt contributed to gRNFL thinning being only at a borderline level (Table 2).

Despite the fact that tRNFL thickness was reduced by 11.8% (8.6 μm) while only a 7.2% (5.4 μm) reduction was observed for rRNFL, the level of significance between the two was similar, possibly due to the much higher intersubject variability of tRNFL thickness.

A similar sensitivity of tRNFL and RGC/IPL in detecting abnormally thin neuronal and axonal layers of RGC in RRMS patients was also demonstrated by ROC analysis. Both parameters showed almost identical area under the curve (AUC 0.72 and 0.73, P = 0.007 and 0.003 for RGC/IPL and tRNFL, respectively; Fig. 5). Area under the curve for gRNFL was 0.67 (P = 0.034). When examining the shape of ROC curves, the sensitivity of RGC/IPL was slightly larger at the highest level of specificity, (although this difference is marginal and would need to be confirmed in a larger set of patients). However, it was noted that the RGC/IPL was thinner than the fifth percentile of normal controls in 21 patients (47%), while tRNFL was reduced only in 17 patients (38%).

Longitudinal Analysis

There was a significant reduction in RGC/IPL and tRNFL thickness during the follow-up period (Repeated measures ANOVA, Table 3). However, pairwise analysis for RGC/IPL demonstrated that the difference was only significant between baseline and year 3, while tRNFL was significant between all years. Temporal-inferior RNFL sector also demonstrated significant difference between all time-points, while temporal-superior and nasal-inferior sectors were significant between baseline and 1 year and baseline and 2 years for temporal-superior sector and baseline and 3 years for nasal-inferior sector.

Because fibers that subserved the central retina demonstrated the greatest thinning among all RNFL sectors in the cross-sectional study, only the temporal RNFL segments were analyzed further.

The reduction of tRNFL was 5.1% (3.04 μm), while RGC/IPL only lost 1.4% (0.96 μm), resulting in mean annual changes of −1.01 μm and −0.32 μm, respectively. This difference was confirmed by ROC analysis, which demonstrated a significant difference in area under the curve between two measures (AUC 0.52 and 0.78, P = 0.7 and <0.001 for RGC/IPL and tRNFL, respectively; Fig. 4). In accordance with this, a progressive rate of thinning exceeding the 95th percentile of change in healthy controls was observed in 24 patients based on tRNFL (53%) and only in 12 patients based on RGC/IPL (27%).

Detection of change of the RGC layer can potentially be affected by the RGC thickness profile as the cells are displaced from the foveal region and their density drops dramatically with retinal eccentricity.2 Therefore, we investigated RGC loss at five different eccentricities (between 2° and 10°) separately. Apart from most peripheral points (which showed minimal loss probably due to a very thin RGC layer), reduction of RGC layer thickness was relatively uniform across the examined retina at approximately 1 to 1.5 μm, which corresponded overall to approximately 2% of RCGL thinning (Table 4).

It has previously been suggested that patients with a history of ON may have more severe loss of RGC and their axons in the fellow eye when compared with patients with no history of

TABLE 2. Mean Thickness of Controls and MS Patients for Each of the Nine Measurement Parameters Chosen and Percentage of Thinning

<table>
<thead>
<tr>
<th></th>
<th>RGC/IPL µm</th>
<th>RNFL µm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NS</td>
<td>N</td>
</tr>
<tr>
<td>Controls</td>
<td>74.2 ± 2.8</td>
<td>69.4 ± 17.0</td>
</tr>
<tr>
<td>CV 3.8%</td>
<td>17.6%</td>
<td>16.1%</td>
</tr>
<tr>
<td>CV 6.8%</td>
<td>8.8%</td>
<td>22.3%</td>
</tr>
<tr>
<td>P value</td>
<td>0.004</td>
<td>0.479</td>
</tr>
<tr>
<td>Thinning</td>
<td>7.2%</td>
<td>−4.2%</td>
</tr>
</tbody>
</table>

Values are mean ± SD.
*

Nonpaired t-test.
Table 3. Progressive Thinning of RGC/IPL and RNFL in MS Patients from Baseline to Year 3 Follow-up

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>RGC/IPL, μm</th>
<th>tRNFL, μm</th>
<th>gRNFL, μm</th>
<th>nsRNFL, μm</th>
<th>nRNFL, μm</th>
<th>niRNFL, μm</th>
<th>tsRNFL, μm</th>
<th>tiRNFL, μm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>68.8 ± 7.6</td>
<td>63.7 ± 11.7</td>
<td>93.0 ± 10.7</td>
<td>101.1 ± 22.8</td>
<td>70.2 ± 13.6</td>
<td>106.8 ± 22.5</td>
<td>128.3 ± 19.6</td>
<td>139.5 ± 21.1</td>
</tr>
<tr>
<td>1 y</td>
<td>68.7 ± 7.8</td>
<td>62.5 ± 12.1</td>
<td>92.0 ± 10.5</td>
<td>100.7 ± 22.9</td>
<td>69.4 ± 14.9</td>
<td>106.9 ± 24.9</td>
<td>127.6 ± 18.1</td>
<td>137.3 ± 21.1</td>
</tr>
<tr>
<td>2 y</td>
<td>68.2 ± 7.4</td>
<td>61.7 ± 12.0</td>
<td>91.3 ± 10.4</td>
<td>100.2 ± 22.1</td>
<td>68.7 ± 13.2</td>
<td>105.9 ± 22.4</td>
<td>126.9 ± 18.2</td>
<td>136.5 ± 21.0</td>
</tr>
<tr>
<td>3 y</td>
<td>67.9 ± 7.9</td>
<td>60.6 ± 12.0</td>
<td>90.6 ± 10.6</td>
<td>101.7 ± 22.5</td>
<td>69.0 ± 13.9</td>
<td>103.3 ± 21.9</td>
<td>126.3 ± 20.2</td>
<td>135.2 ± 21.1</td>
</tr>
</tbody>
</table>

*C* value*  0.002  < 0.001  < 0.001  0.3  0.051  0.01  0.01  < 0.001
% loss  1.4  5.1  2.6  −0.5  1.7  3.0  1.6  3.1

Values are mean ± SD.

* Repeated measures ANOVA.

Figure 3. ROC analysis at baseline. (A) Baseline RGC/IPL thickness ROC curve. AUC = 0.72, asymptotic significance, <0.007. (B) Baseline tRNFL thickness ROC curve. AUC = 0.73, asymptotic significance, <0.003.

Figure 4. ROC curves for longitudinal change in thickness from baseline to 3 years follow-up. (A) Longitudinal RGC/IPL thickness ROC curve. AUC = 0.52, asymptotic significance, <0.7. (B) Longitudinal tRNFL thickness ROC curve. AUC = 0.78, asymptotic significance, <0.001.
ON (so called Phenotype effect). Therefore, we further separated patients into two groups based on the history of ON. While fellow eyes of ON patients did show a slightly higher rate of progression for all parameters, the difference was not statistically significant (P > 0.05 for all, Table 5). As expected, ON eyes demonstrated considerably thinner baseline thickness (54.5 ± 9.8, 45.5 ± 11.9, and 74.8 ± 11.8 μm for GCL, tRNFL and gRNFL, respectively) and smaller loss during follow-up (−0.28 ± 1.3 (0.5%), −1.2 ± 2.3 (2.7%), and −1.4 ± 2.6 μm (1.9%) for GCL, tRNFL, and gRNFL, respectively).

There was no difference between males and females at baseline or between rates of progression for RGC/IPL, tRNFL, and gRNFL (P > 0.05 for all). None of the parameters demonstrated a significant relationship with duration of the disease (P > 0.05 for all).

**DISCUSSION**

Neuronal and axonal loss of RGC in MS patients with no previous history of optic neuritis is well documented. Significant thinning of neuroretina was demonstrated at very early stages of the disease and even before clinical onset of the MS. Several studies examining both RNFL and RGC layer thickness indicated a better sensitivity of the RGC layer in distinguishing MS patients from healthy controls and better correlation of RGC layer thickness with visual acuity and brain atrophy measures. However, in the majority of those studies only analysis of global RNFL was used, which may explain the disadvantage in axonal measurement. We have previously reported that in NON eyes of MS patients the tRNFL is reduced relatively more than gRNFL.

Progressive changes in axonal and neuronal structure of RGC in NON eyes of MS patients is, however, more difficult to establish. While some studies demonstrated thinning of RNFL and RGC layer, others found changes in one parameter, but not in the other, while other groups did not find measurable changes in either layer. Several factors, such as variable (sometimes even within one study) follow-up period, different resolution of the equipment used, methodological aspects of retinal segmentation and patients selection may account for this discordance. In addition, the RNFL/GCL parameter measured differs between studies. Thus, while the advantage of measuring progressive thinning of RGC layer over the change in RNFL in NON eyes of MS patients has recently been shown by Narayanan et al. and Ratchford et al., both studies only analyzed global RNFL, which is not optimal to detect subtle loss of RGC axons.

Therefore, this study targeted the rate of RGC and RNFL change in NON eyes of RRMS patients followed annually over 3 years compared with a group of age, sex, and race-matched controls in order to find the best OCT parameter to both identify disease and monitor progression accurately. Cross-sectional evaluation of RNFL and RGC/IPL thickness confirmed both neuronal and axonal damage. Despite the larger relative thinning of tRNFL, measurement of RGC/IPL revealed a similar rate of abnormality in identifying MS patients when ROC analysis was applied. Using fifth percentile of thickness in normal controls as a cut-off point, more eyes demonstrated abnormality when RGC/IPL layer was used compare with RNFL (21 vs. 17).

It is also worth noting that not all RNFL segments were equally affected, the largest effect was seen in the temporal sector following by two surrounding (TI and TS) areas, while none of the nasal sectors demonstrated significant thinning. Because gRNFL is calculated based on averaged values of all sectors, this may explain low sensitivity of global RNFL, found in previous publications.

The longitudinal study, however, revealed that tRNFL performed considerably better than RGC/IPL in detecting progressive loss. Several potential reasons may account for this. The higher sensitivity of RGC/IPL thinning in previous cross-sectional studies may be related to intersubject differences. Intersubject variability is generally much tighter for RGC/IPL thickness measurements compared to RNFL. For example, in our cohort of healthy controls the coefficient of variability was more than four times larger for tRNFL thickness compared with RGC/IPL. A number of factors can affect the accuracy of...
Changes in the RGC Layer and RNFL of NON Eyes

peripapillary RNFL measurement and therefore, its intersubject variability including disc size. In addition, temporal RNFL in particular is significantly affected by optic disc tilt (frequently associated with myopia) and unless this is controlled for in the study design, a wider range of tRNFL variability may be expected. Race is another factor, which affects RNFL measurements. Our study did not specifically adjust for disc size or myopia, but there were no evident outliers in disc size, no high myopes and all subjects were Caucasian.

Alternatively, there are several factors, which may contribute to the better performance of tRNFL in detecting progressive change. First, the effect of intersubject variability described above is eliminated by longitudinal analysis. Second, the ability of the combined RGC/IPL to detect change over time may be limited by a relative preservation of IPL, which contributes approximately 40% to 60% of the combined layer and masks, therefore, any reduction of RGC layer thickness. Because density of RGC peaks at approximately 2 to 4 of retinal eccentricity and then rapidly declines, while IPL thickness remains relatively constant throughout the central retina we speculated that examination of combined RGC/IPL at more central retinal locations may show larger progressive thickening. However, a similar degree of loss (~2%) was found at all, except the most peripheral, eccentricities.

Third, small diameter axons comprising temporal RNFL bundle may be more susceptible to MS damage compare with large diameters fibers subserving more peripheral retina. Finally, preferential damage of tRNFL fibers may also be related to retrograde transsynaptic degeneration from optic radiation (OR) lesions, which are frequently seen in MS patients. More than 50% of visual cortex subserves the central 10 of the retina. This over-representation of the central visual field is largely formed at the retinal level and preserved in the OR. Assuming a uniform distribution of MS lesions within the OR, it is likely that OR fibers subserving central vision are damaged more frequently, which in turn may cause more extensive thinning of tRNFL fibers. Taken together, those factors may help to explain better performance of the tRNFL in analyzing progressive loss.

Recent studies have demonstrated a topographic location of retinal ganglion cell death is associated with clock-hour location of pRNFL loss in glaucoma patients. The RGC protocol of the Spectralis system used in this study, however, did not allow us to perform a sectoral analysis similar to that used by the Cirrus OCT (Carl Zeiss Meditec AG, Jena, Germany). As a result there is a lack of ability to perform direct comparisons with other RGC studies, representing a limitation of the study. However, an advantage of the technique employed was that we are able to determine the rate of change with eccentricity from the fovea did not vary significantly, and this has not previously been reported.

Because we included only patients with relapsing-remitting disease, our results cannot be extrapolated to other types of MS or to patients with very advanced disease. Progressive types may cause higher rates of atrophy of the retinal layers and previous studies have shown RNFL thickness varies with disease subtype. It has to be noted, however, that none of the parameters correlated with disease duration.

Most of the patients in this study were on disease-modifying therapies, and it is, therefore, possible that our results may underestimate true rates of retinal atrophy, which might be higher in an untreated study cohort. There was also some variability in terms of the types of disease-modifying therapies patients were undergoing, not only at their baseline visit, but also for the duration of the study. This variability in disease-modifying therapies throughout the study duration prevented assessment of the effects of these treatments on our results. Future studies including more homogeneously treated subgroups would possibly allow a more accurate calculation of the effects of these therapies on the rate of retinal atrophy.

In conclusion, our study demonstrated that RGC/IPL thickness and RNFL both indicate neuroretinal damage in a cross-sectional analysis in NON eyes of RRMS patients, while tRNFL showed the best sensitivity in detecting progressive thinning. The findings of this study should assist both clinicians managing the disease and in the design of clinical trials where axonal degeneration and neuronal loss in MS patients are monitored and used as biomarkers.

Acknowledgments

Supported by Save Neuron grant (Novartis; Sydney, NSW, Australia), the Sydney Eye Hospital Foundation (Sydney, NSW, Australia) and a grant from the National MS Society (New York City, NY, USA).

Disclosure: E.C. Graham, None; Y. You, None; C. Yiannikas, None; R. Garrick, None; J. Parratt, None; M.H. Barnett, None; A. Klistorner, None

References


Investigative Ophthalmology & Visual Science

Table of Contents: Click here to view

ISSN: 0146-0404
Title: Investigative Ophthalmology & Visual Science

Publishing Body: Association for Research in Vision and Ophthalmology
Country: United States
Status: Active
Start Year: 1962
Frequency: Monthly

Abstracted/Indexed: Yes
Refereed: Yes

Media: Print
Alternate Edition ISSN: 1552-5783

RSS Availability: Click here to view

Language: Text in English
Price: USD 550 combined subscription per year domestic to individuals (Print & Online Eds.) USD 775 combined subscription per year foreign to individuals (Print & Online Eds.) USD 805 combined subscription per year domestic to institutions (Print & Online Eds.) USD 985 combined subscription per year foreign to institutions (Print & Online Eds.) USD 365 combined subscription per year domestic to students (Print & Online Eds.) USD 585 combined subscription per year foreign to students (Print & Online Eds.) Free to members (effective 2009)

Subject: MEDICAL SCIENCES - OPHTHALMOLOGY AND OPTOMETRY
Dewey #: 617.7
LC#: RE1
CODEN: IOVSDA
Circulation: 6800 unspecified

Special Features: Includes Advertising, Illustrations
Article Index: Index
Editor(s): Paul L Kaufman (Editor-in-Chief)
E-Mail: iovs@arvo.org
URL: http://www.iovs.org

Description: Contains original scientific articles concerning diagnosis, treatment and management of diseases of the ocular complex.

ADDITIONAL TITLE INFORMATION

Alternate Title: Medline Abbreviated title: Invest Ophthalmol Vis Sci; Variant title: I O V S
Title History: Formerly (until 1977): Investigative Ophthalmology (United States) (0020-9988)